{
  "trial_id": "NCT03781310",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "RA according to the ACR 1987 or 2010 criteria",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Current use of tocilizumab IV, with a consistent interval of 4 weeks for at least 24 weeks.",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "18 years of age and older",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "A potential subject will be excluded from participation in case of a scheduled surgery in the next 20 weeks or other preplanned reasons for treatment discontinuation.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "Children, pregnant women and individuals with a lack of judgement",
      "label": "does_not_trigger",
      "evidence": "unknown"
    }
  ],
  "notes": "The patient has been diagnosed with Wegener's granulomatosis and is currently being treated with corticosteroid and cyclophosphamides. His Birmingham Vasculitis Activity Score (BVAS) is above 4, indicating active disease.",
  "_meta": {
    "topic_id": "54",
    "trial_id": "NCT03781310",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}